Background: Digitalization of healthcare led to the optimization of monitoring, diagnostics, and treatment of the range of disorders. Taking into account recent situation with COVID-19 pandemics, digital technologies allowed to improve management of viral infections via remote monitoring and diagnostics of infected patients. Up to date, various mobile health applications (apps) have been proposed, including apps for the patients diagnosed with cardiovascular pathologies. Objective: The presented review aimed at the analyses of a range of mHealth solutions used to improve primary cardiac care. In addition, we studied the factors driving and hindering the wide introduction of mHealth services in the clinics. Methods: The work was based on the guidelines of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. The publication search was carried out using PubMed, Web of Science, Cochrane Library, Scopus, and Google Scholar databases. Studies published during the period from 2014 until January 2022 were selected for the analysis. The evaluation of risk of bias for the included studies was conducted using the Cochrane Collaboration Risk of Bias tool. Results and Discussion: An overall 5513 studies were assessed for eligibility after which 39 studies were included.. The main trend in the mobile health for cardiological applications is the use of different types of wearable devices and Artificial Intelligence-platforms. In fact, mobile technology allows remotely to monitor, interpret, and analyze biomedical data collected from the patient. Conclusion: The results of this literature search demonstrated that patients diagnosed with cardiovascular disorders can potentially benefit from the application of mHealth in cardiology. However, despite the proven advantages of mHealth for cardiology, there are many challenges and concerns regarding effectiveness, safety, reliability and the lack of official regulation and guidelines from official organizations. Such issues require solutions and further work towards a wide implementation of mHealth technologies in cardiac practice.
The 4th Maastricht Consensus Conference on Thrombosis (MCCT), included the following themes: Theme 1: The “coagulome” as a critical driver of cardiovascular disease Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow and kidney. Four investigators shared their views on these organ-specific topics. Theme 2: Novel mechanisms of thrombosis Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infections associated-coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding. Theme 3: How to limit bleeding risks: insights from translational studies This theme included state of the art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed. Theme 4: Hemostasis in extracorporeal systems: how to utilize ex vivo models? Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularised organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation (ECMO) associated coagulopathy are discussed. Theme 5: Clinical dilemmas in thrombosis and antithrombotic management Plenary presentations addressed controversial areas, ie thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies and clinically tested factor XI(a) inhibitors,both possibly with reduced bleeding risk. Finally, Covid-19 associated coagulopathy is revisited.
Relevance: Cervical cancer is the fourth leading cause of female death and the third most common female cancer worldwide. The purpose of the study was to determine risk factors and time to progression and recurrence in patients with cervical cancer after complex treatment (neoadjuvant chemotherapy + radical hysterectomy + combined radiation therapy). Materials and methods: This retrospective study involved female patients with stage IB-IIA cervical cancer registered at Shymkent city oncological dispensary in 2011-2021 (n=883). All patients underwent radical hysterectomy with pelvic lymph node dissection. The patients were selected who underwent radiation therapy of the lower pelvis at a dose of ≥40 g. The age-, stage-, and tumor morphological structure-dependent survival factors and recurrence risk were analyzed during the research decade. Results: Direct correlation of the disease stage and the recurrence period was established. The progression was most often 5 to 6 months after treatment. 68.7% of progression and 63.1% of recurrences occurred in the first year and a half after the end of treatment, so this period is considered the most “dangerous” regarding the recurrence risk. 5.3% of patients had a recurrence 19 to 24 months after treatment, 31.5% – after more than two years. Conclusions: In this research, cervical cancer progressed in 74 (10.6%) out of 883 women and recurred in 19 (3.0%). The recurrence was most frequent in women aged 45-50 years (28.4%) and 50-60 years (26.3%).
th and the third most common female cancer worldwide. The purpose of the study was to determine risk factors and time to progression and recurrence in patients with cervical cancer after complex treatment (neoadjuvant chemotherapy + radical hysterectomy + combined radiation therapy). Methods: This retrospective study involved female patients with stage IB-IIA cervical cancer registered at Shymkent city oncological dispensary in 2011- 2021 (n=883). All patients underwent (n=883) radical hysterectomy with pelvic lymph node dissection. The patients were selected who underwent radiation therapy of the lower pelvis at a dose of ≥40 g. The age-, stage-, and tumor morphological structure-dependent survival factors and recurrence risk were analyzed during the research decade. Results: Direct correlation of the disease stage and the recurrence period was established. The progression was most often 5 to 6 months after treatment. 68.7% of progression and 63.1% of recurrences occurred in the first year and a half after the end of treatment, so this period is considered the most “dangerous” regarding the recurrence risk. 5.3% of patients had a recurrence 19 to 24 months after treatment, 31.5% – after more than two years. Conclusions: In this research, cervical cancer progressed in 74 (10.6%) out of 883 women and recurred in 19 (3.0%). The recurrence was most frequent in women aged 45-50 years (28.4%) and 50-60 years (26.3%).
This article presents the results of a survey of 1734 outpatient patients with oncological diseases from South Kazakhstan region. Altogether, 34 multidisciplinary outpatient medical institutions were included into the survey. 72.1 (95 % CI: 70,0-74,2) % of the patients were satisfied with outpatient medical care. 15.7 % of the patients (95 % CI 14,1-17,5) were unsatisfied. Binary logistic regression revealed the factors which influenced dissatisfaction with outpatient medical care. These were problems with making an appointment with a physician (OR 24.5 (95 % CI: 16.4; 36.7)), waiting time for more than 30 min (OR 1.6 (95 % CI: 1.0; 2.4)), male gender (OR 1.4 (95 % CI: 1.0; 2.0)) and rural residence (OR 2.7 (95 % CI: 2.0; 3.8)). According to results of the survey we highlighted the importance of the outpatient medical care optimization in Kazakhstan.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.